Katarzyna Reszka

Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations

Paweł Krawczyk, Dariusz M. Kowalski, Rodryg Ramlau et al. · Oncology Letters · 2017 · 64 citations · Full text

Medicine, Oncology, Pharmacology +14

Impact of copy number variant and single nucleotide polymorphism of the programmed death‑ligand 1 gene, programmed death‑ligand 1 protein expression and therapy regimens on overall survival in a large group of Caucasian patients with non‑small cell lung carcinoma

Anna Grenda, Paweł Krawczyk, Tomasz Kucharczyk et al. · Oncology Letters · 2021 · 29 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Correlation between KRAS, NRAS and BRAF mutationsand tumor localizations in patients with primaryand metastatic colorectal cancer

Aleksandra Bożyk, Paweł Krawczyk, Katarzyna Reszka et al. · Archives of Medical Science · 2021 · 23 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Tissue MicroRNA Expression as a Predictor of Response to Immunotherapy in NSCLC Patients

Anna Grenda, Paweł Krawczyk, Justyna Błach et al. · Frontiers in Oncology · 2021 · 16 citations · Full text

Medicine, Molecular Biology, Oncology +17

Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predictmetastases in colorectal cancer: A preliminary study

Kamila Wojas‐Krawczyk, Ewa Kalinka‐Warzocha, Katarzyna Reszka et al. · Advances in Clinical and Experimental Medicine · 2018 · 14 citations · Full text

Medicine, Molecular Genetics, Oncology +17